Ace the NAPLEX 2025 – Unlock Your Pharmacist Potential Today!

Lasmiditan (Reyvow) is not contraindicated in patients with cardiovascular disease (CVD) because it does not cause vasoconstriction. This is a crucial point because vasoconstriction can potentially worsen cardiovascular conditions by increasing the workload on the heart and narrowing blood vessels, leading to increased blood pressure. Since Lasmiditan does not cause vasoconstriction, it is considered safer for patients with pre-existing cardiovascular conditions.

Options B, C, and D are incorrect:

- Option B stating that Lasmiditan is a non-selective serotonin receptor antagonist is not a reason why it is not contraindicated in CVD. In fact, the mechanism of action of Lasmiditan, which involves selective agonism of the 5-HT1F receptor, is unrelated to its safety in CVD.

- Option C mentioning no interaction with CYP3A4 inhibitors and Option D stating that it is not metabolized by the liver are also not directly related to why Lasmiditan is not contraindicated in patients with CVD. While these factors may play a role in drug interactions and metabolism, they do not explain the safety of Lasmiditan in patients with CVD.